Methods of treating pancreatic cancer
Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.
1. A method of treating pancreatic cancer in a human individual comprising administering to the individual (a) an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin; and (b) an effective amount of gemcitabine, wherein the pancreatic cancer is borderline resectable pancreatic cancer.
2. The method of claim 1 , wherein the pancreatic cancer is pancreatic adenocarcinoma.
3. The method of claim 1 , wherein the individual has Karnofsky performance status (KPS) of between 70 and 80.
4. The method of claim 1 , wherein the individual has a high level of hENT1 (human equilibrative nucleoside transporter 1).
5. The method claim 1 wherein the composition comprising nanoparticles comprising paclitaxel and an albumin is administered intravenously.
6. The method of claim 1 , wherein the dose of paclitaxel in the nanoparticle composition is about 50 mg/m 2 to about 200 mg/m 2 .
7. The method of claim 6 , wherein the dose of paclitaxel in the nanoparticle composition is about 125 mg/m 2 .
8. The method of claim 6 , wherein the composition comprising nanoparticles comprising paclitaxel and albumin is administered weekly, three out of four weeks.
9. The method of claim 1 , wherein the albumin is human serum albumin.
10. The method of claim 1 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.
11. The method of claim 1 , wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1 or less.
12. The method of claim 1 , wherein the paclitaxel in the nanoparticles is coated with the albumin.
13. The method of claim 1 , wherein gemcitabine is administered to the individual at about 500 mg/m 2 to about 2000 mg/m 2 .
14. The method of claim 13 , wherein gemcitabine is administered to the individual at about 1000 mg/m 2 .
15. The method of claim 13 , wherein gemcitabine is administered weekly, three out of four weeks.
16. The method of 13 , wherein gemcitabine is administered intravenously.
17. The method of claim 1 , wherein the method is for first-line treatment.